A Phase 1b Dose-escalating Study With RBT-1, in Healthy Volunteers and Subjects With Chronic Kidney Disease Stage 3b-4
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Iron-sucrose/tin-protoporphyrin (Primary)
- Indications Renal failure
- Focus Biomarker; Pharmacodynamics
- Sponsors Renibus Therapeutics
- 22 Aug 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 22 Aug 2018 New trial record